Soligenix Shares Rise On Receiving FDA IND Clearance For Phase 2 Clinical Trial Of Dusquetide
Shares of Soligenix, Inc. (SNGX) are up 364% on Thursday following the announcement that the FDA has given clearance to its Investigational New Drug (IND) application for a Phase 2a clinical trial of Dusquetide.
Source: rttnews.com